Patents Assigned to Takara Bio, Inc.
-
Publication number: 20240309341Abstract: Provided are: a DNA polymerase mutant having reverse transcriptase activity, the DNA polymerase mutant including a sequence consisting of twelve specific amino acids A1-A12, wherein the DNA polymerase mutant having reverse transcriptase activity is characterized in that the A3 and/or A10 amino acid is substituted by a basic amino acid residue different from that prior to the introduction of mutation; a kit and a composition including the DNA polymerase; a method for producing the DNA polymerase; and a method for modifying an existing DNA polymerase having reverse transcriptase activity.Type: ApplicationFiled: May 10, 2024Publication date: September 19, 2024Applicant: Takara Bio Inc.Inventors: Takashi UEMORI, Hiroyuki Matsumoto, Kensuke Saito, Miwa Akitomo
-
Patent number: 12018294Abstract: Provided are: a DNA polymerase mutant having reverse transcriptase activity, the DNA polymerase mutant including a sequence consisting of twelve specific amino acids A1-A12, wherein the DNA polymerase mutant having reverse transcriptase activity is characterized in that the A3 and/or A10 amino acid is substituted by a basic amino acid residue different from that prior to the introduction of mutation; a kit and a composition including the DNA polymerase; a method for producing the DNA polymerase; and a method for modifying an existing DNA polymerase having reverse transcriptase activity.Type: GrantFiled: July 3, 2019Date of Patent: June 25, 2024Assignee: TAKARA BIO INC.Inventors: Takashi Uemori, Hiroyuki Matsumoto, Kensuke Saito, Miwa Akitomo
-
Patent number: 12018276Abstract: In the present invention, lymphocytes are efficiently grown by culturing lymphocytes in the presence of a novel recombinant fibronectin fragment.Type: GrantFiled: January 24, 2019Date of Patent: June 25, 2024Assignee: TAKARA BIO INC.Inventors: Tomomi Otsuji, Yuka Hirase, Asako Hatsuyama, Sachiko Okamoto, Tatsuji Enoki, Junichi Mineno
-
Patent number: 11999972Abstract: Stem cells can be efficiently proliferated by culturing the stem cells in the presence of a novel recombinant fibronectin fragment.Type: GrantFiled: July 28, 2017Date of Patent: June 4, 2024Assignee: TAKARA BIO INC.Inventors: Tomomi Otsuji, Toshikazu Nishie, Risa Kato, Sachiko Okamoto, Tatsuji Enoki, Junichi Mineno
-
Publication number: 20230330214Abstract: Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.Type: ApplicationFiled: September 30, 2021Publication date: October 19, 2023Applicants: OSAKA UNIVERSITY, TAKARA BIO INC., ANGES, INC.Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Hiroki HAYASHI, Yasunori AMAISHI, Sachiko OKAMOTO, Junichi MINENO, Hisato IKAI, Junko MICHIBATA, Takao KOMATSUNO
-
Publication number: 20230160023Abstract: Provided is a method for detecting an FNA virus in a biological sample, the method comprising: (1) a step for preparing a sample solution containing a biological sample, a protease, a nucleic acid that does not become a target of nucleic acid amplification, and at least one additive selected from the group consisting of chaotropic reagents and surfactants; (2) a step for preparing a nucleic acid amplification reaction solution containing the sample solution prepared in step (1) and containing a polypeptide having reverse transcriptase activity and DMA polymerase activity or a polypeptide having reverse transcription activity and a polypeptide having DNA polymerase activity; and (3) a step for amplifying a nucleic acid of the RNA virus in the reaction solution prepared in step (2).Type: ApplicationFiled: April 28, 2021Publication date: May 25, 2023Applicant: TAKARA BIO INC.Inventors: Takashi UEMORI, Takehiro SAGARA, Miwa AKITOMO, Kensuke SAITO
-
Publication number: 20230133071Abstract: The present invention provides a GG-specific mismatch endonuclease variant, a TT-specific mismatch endonuclease variant, and a GT/TG-specific mismatch endonuclease variant. The present invention also provides a mismatch specific cleaving reaction using said variant, a method for removing errors in a nucleic acid amplification reaction using a mismatch nuclease, a method for suppressing amplification of a nucleic acid having a specific base sequence during a nucleic acid amplification reaction, and a method for detecting a nucleic acid having a single base polymorphic mutation using said suppression method.Type: ApplicationFiled: March 18, 2021Publication date: May 4, 2023Applicants: TAKARA BIO INC., EDUCATIONAL CORPORATION KANSAI BUNRI SOUGOUGAKUEN, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Hiroyuki MATSUMOTO, Takashi UEMORI, Tsuyoshi SHIRAI, Yoshizumi ISHINO, Sonoko ISHINO
-
Patent number: 11572580Abstract: The present invention pertains to: an oligonucleotide preservation method; and a kit comprising an oligonucleotide. The present invention provides a method for stably preserving an oligonucleotide-containing solution by adding a nucleic acid-binding protein to said oligonucleotide-containing solution in advance.Type: GrantFiled: June 6, 2018Date of Patent: February 7, 2023Assignee: TAKARA BIO INC.Inventors: Miwa Akitomo, Takashi Uemori
-
Publication number: 20220372516Abstract: Provided is a nucleic acid construct for expressing a gene of interest, the nucleic acid construct comprising, in order from 5?-terminus, each sequence of: (a) a 5? long terminal repeat (LTR) sequence derived from a retrovirus; (b) a packaging signal sequence (IV) derived from a retrovirus; (c) a sequence or multiple cloning site of the gene of interest; (d) a post-transcriptional regulatory sequence (PRE); (e) an siRNA generating sequence which forms at least one stem-loop structure and in which RNA, which induces RNA interference in mammalian cells, is transcribed; and (f) a 3? LTR sequence derived form a retrovirus.Type: ApplicationFiled: October 9, 2020Publication date: November 24, 2022Applicant: TAKARA BIO INC.Inventors: Sachiko OKAMOTO, Izumi MAKI, Junichi MINENO
-
Patent number: 11473057Abstract: The purpose of the present invention is to efficiently produce microglia from pluripotent stem cells. Provided is a method for producing microglia from pluripotent stem cells, comprising the following steps: (a) a step of co-culturing a pluripotent stem cell together with a feeder cell for 7 days or longer, and obtaining a blood progenitor cell; (b) a step of co-culturing the blood progenitor cell obtained in step (a) together with a feeder cell in the presence of IL-3 and/or GM-CSF, and obtaining an embryonic monocyte; and (c) a step of, in the presence of M-CSF, co-culturing the embryonic monocyte obtained in step (b) together with an astrocyte, or culturing the embryonic monocyte using an astrocyte supernatant.Type: GrantFiled: September 1, 2017Date of Patent: October 18, 2022Assignee: TAKARA BIO INC.Inventor: Hiroki Saito
-
Publication number: 20220235375Abstract: A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D? region in an AAV inverted terminal repeat (ITR) (i.e., an AD sequence) or a sequence complementary to the AD sequence and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into a cell capable of producing an AAV hollow particle; and (3) culturing the cell obtained in step (2).Type: ApplicationFiled: July 2, 2020Publication date: July 28, 2022Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, TAKARA BIO INC.Inventors: Takashi OKADA, Junichi MINENO, Hideto CHONO
-
Publication number: 20220162637Abstract: The present invention provides a nucleic acid which encodes an adeno-associated virus (AAV) capsid protein mutant that contains a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62 or a peptide comprising an amino acid sequence produced by substituting, deleting, inserting and/or adding one or several amino acid residues in an amino acid sequence selected from the group consisting of SEQ ID Nos. 15 to 62; DNA comprising the nucleic acid; a cell harboring the DNA; and a method for producing the cell.Type: ApplicationFiled: April 23, 2020Publication date: May 26, 2022Applicant: TAKARA BIO INC.Inventors: Toshikazu NISHIE, Fuyuko TAKASHIMA, Tatsuji ENOKI, Junichi MINENO, Yoshinori TANAKA
-
Patent number: 11225643Abstract: The present invention relates to a method for producing endothelial cells, including carrying out: (a) inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body; and (b) culturing the population of mesoderm-lineage cells containing endothelial progenitor cells in the presence of RepSox, in this order. According to the present invention, endothelial cells with high quality can be efficiently produced from pluripotent stem cells. The endothelial cells obtained by the method of the present invention are useful for the production of, for example, a myocardial sheet, and expected to be utilized in the treatment of a heart disease. A myocardial sheet can be produced by mixing the endothelial cells obtained by the method of the present invention with myocardial cells and mural cells and culturing the cells.Type: GrantFiled: December 1, 2017Date of Patent: January 18, 2022Assignee: TAKARA BIO INC.Inventors: Yuki Yamamoto, Tatsuji Enoki, Yasuhiro Tosaka, Yoko Yamaguchi, Junichi Mineno
-
Patent number: 11220677Abstract: Provided are: a reverse transcriptase mutant including an amino acid mutation at a position corresponding to position 55 of the amino acid sequence of wild-type reverse transcriptase derived from the Moloney murine leukemia virus, wherein the reverse transcriptase mutant is characterized in that the amino acid mutation is a substitution from threonine to another amino acid, and the other amino acid is selected from the group consisting of amino acids having a nonpolar aliphatic side chain and amino acids having a polar acidic functional group side chain; a nucleic acid that encodes the mutant; a method for producing the mutant and the nucleic acid that encodes the mutant; a method for synthesizing cDNA in which the mutant is used; and a composition and kit including the mutant.Type: GrantFiled: December 13, 2017Date of Patent: January 11, 2022Assignee: TAKARA BIO INC.Inventors: Kazuhiko Ishikawa, Takashi Uemori, Nariaki Takatsu
-
Publication number: 20210277367Abstract: Provided are: a reverse transcriptase mutant including an amino acid mutation at a position corresponding to position 55 of the amino acid sequence of wild-type reverse transcriptase derived from the Moloney murine leukemia virus, wherein the reverse transcriptase mutant is characterized in that the amino acid mutation is a substitution from threonine to another amino acid, and the other amino acid is selected from the group consisting of amino acids having a nonpolar aliphatic side chain and amino acids having a polar acidic functional group side chain; a nucleic acid that encodes the mutant; a method for producing the mutant and the nucleic acid that encodes the mutant; a method for synthesizing cDNA in which the mutant is used; and a composition and kit including the mutant.Type: ApplicationFiled: December 13, 2017Publication date: September 9, 2021Applicant: TAKARA BIO INC.Inventors: Kazuhiko ISHIKAWA, Takashi UEMORI, Nariaki TAKATSU
-
Publication number: 20210254018Abstract: Stem cells can be efficiently proliferated by culturing the stem cells in the presence of a novel recombinant fibronectin fragment.Type: ApplicationFiled: July 28, 2017Publication date: August 19, 2021Applicant: TAKARA BIO INC.Inventors: Tomomi OTSUJI, Toshikazu NISHIE, Risa KATO, Sachiko OKAMOTO, Tatsuji ENOKI, Junichi MINENO
-
Publication number: 20210246173Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.Type: ApplicationFiled: April 29, 2021Publication date: August 12, 2021Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
-
Publication number: 20210222137Abstract: Provided are: a DNA polymerase mutant having reverse transcriptase activity, the DNA polymerase mutant including a sequence consisting of twelve specific amino acids A1-A12, wherein the DNA polymerase mutant having reverse transcriptase activity is characterized in that the A3 and/or A10 amino acid is substituted by a basic amino acid residue different from that prior to the introduction of mutation; a kit and a composition including the DNA polymerase; a method for producing the DNA polymerase; and a method for modifying an existing DNA polymerase having reverse transcriptase activity.Type: ApplicationFiled: July 3, 2019Publication date: July 22, 2021Applicant: TAKARA BIO INC.Inventors: Takashi UEMORI, Hiroyuki MATSUMOTO, Kensuke SAITO, Miwa AKITOMO
-
Patent number: 11046939Abstract: The present invention relates to a Thermus aquaticus (Taq) polymerase having a strand displacement activity in which an amino acid residue in a template DNA binding site of the DNA polymerase is substituted with an amino acid to increase a total charge in the site, a nucleic acid encoding the polymerase, a vector containing the nucleic acid, a transformant containing the vector containing the nucleic acid or the nucleic acid, a method for producing the polymerase, a method for amplifying nucleic acids utilizing the polymerase, and a kit containing the polymerase. According to the present invention, a DNA polymerase having a high thermostability, capable of efficiently replicating a long-strand of a template DNA, and having a strong strand displacement activity is provided.Type: GrantFiled: November 24, 2016Date of Patent: June 29, 2021Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TAKARA BIO INC.Inventors: Yoshizumi Ishino, Sonoko Ishino, Takeshi Yamagami, Takashi Uemori, Nariaki Takatsu
-
Patent number: 11028131Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.Type: GrantFiled: January 29, 2018Date of Patent: June 8, 2021Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno